Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chenodeoxycholic acid - Mirum Pharmaceuticals

Next Previous
X
Search
Drug Profile

Chenodeoxycholic acid - Mirum Pharmaceuticals

Alternative Names: Chenodal®; Chenodiol - Mirum Pharmaceuticals

Latest Information Update: 26 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mirum Pharmaceuticals
  • Class Choleretics; Cholic acids; Gallstone therapies; Gastrokinetics; Irritable bowel syndrome therapies
  • Mechanism of Action Cholesterol modulators; Cholesterol synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cerebrotendinous xanthomatosis
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Cerebrotendinous xanthomatosis

Most Recent Events

  • 13 Jul 2024 Chenodeoxycholic acid - Mirum Pharmaceuticals receives Orphan Drug status for Cerebrotendinous xanthomatosis in USA, as at March 2010
  • 28 Jun 2024 Preregistration for Cerebrotendinous xanthomatosis (In adolescents, In children, In the elderly, In infants, In adults) in USA (PO)
  • 04 Oct 2023 Mirum Pharmaceuticals completes the phase III RESTORE trial in Cerebrotendinous xanthomatosis (In infants, In children, In adolescents, In adults, In the elderly) in Brazil, USA (PO) (NCT04270682)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top